Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Graft-Versus-Host Disease

 

Cyclophosphamide for Preventing Graft-Versus-Host Disease (FHCRC-2541)
A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation

Investigator: Marco Mielcarek, MD;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01427881

Imatinib Mesylate and Rituximab in Treating Cutaneous Sclerosis for Chronic GVHD (FHCRC-2343)
A Randomized Phase 2 Study of Imatinib and Rituximab for Cutaneous Sclerosis in Patients with Chronic Graft-Versus-Host Disease

Investigator: Mary Flowers, MD;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01309997

Alefacept for Steroid-Refractory Chronic GVHD (2469)
A Phase II, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in Subjects with Steroid-Refractory Chronic Graft-versus-Host Disease

Investigator: Stephanie Lee, MD, MPH;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01226420

Tacrolimus + Mycophenolate Mofetil Post Transplant (FHCRC-1898)
A Multi-Center Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil

Investigator: David Maloney, MD, PhD;   Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases;    Status: Closed;   Study ID: NCT00089011

Chronic Graft-versus-Host Disease Treatment (FHCRC-2375)
A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, Sirolimus/Extracorporeal Photopheresis plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN 0801)

Investigator: Paul Carpenter, MD;   Conditions: Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT);    Status: Closed;   Study ID: NCT01106833

Nilotinib in Steroid Dependent / Refractory Chronic GVHD (2423)
A Phase 1 Study of Nilotinib in Steroid Dependent / Refractory Chronic Graft Versus Host Disease

Investigator: Paul Carpenter, MD;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01155817

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing GVHD for Undergoing Donor Peripheral Blood Stem Cell Transplant (FHCRC-2206)
A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate mofetil (MMF) for Prevention of Acute GVHD after Non-myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation. A Multi-Center Trial

Investigator: Brenda Sandmaier, MD;   Conditions: Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT01251575

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (FHCRC-2448)
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial

Investigator: Brenda Sandmaier, MD;   Conditions: Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT01231412

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant (FHCRC-1825)
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multicenter Trial

Investigator: Brenda Sandmaier, MD;   Conditions: Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphoid Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma (MM), Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD), Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT00096161

Depletion of T Cells From Allogeneic Stem Cell Grafts for the Prevention of GVHD (FHCRC-2222)
A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Investigator: Marie Bleakley, MD;   Conditions: Acute Lymphoid Leukemia (ALL);, Acute Myeloid Leukemia (AML), Hematologic Malignancies, Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD);    Status: Recruiting;   Study ID: NCT00914940

Sirolimus-Based Graft Versus Host Disease Prophylaxis Post Transplant (COG ASCT0431)
A Randomized Trial Of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplant

Investigator: Jean Sanders, MD;   Conditions: Graft Versus Host Disease, Leukemia;    Status: Closed;   Study ID: NCT00382109

Montelukast for Bronchiolitis Obliterans Post Transplant (2317)
Multi-Institutional Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults

Investigator: Paul Martin, MD;   Conditions: Bronchiolitis Obliterans, Chronic Graft-versus-host Disease;    Status: Closed;   Study ID: NCT00656058

Targeted Therapy of Bronchiolitis Obliterans Syndrome (2367)
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

Investigator: Paul Martin, MD;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01307462

Low-Dose Prednisone or Methylprednisolone for GVHD (FHCRC-2327)
A Phase III Study to Assess Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease

Investigator: Marco Mielcarek, MD;   Conditions: Graft Versus Host Disease;    Status: Recruiting;   Study ID: NCT00929695

Alpha 1 Anti-Trypsin for Acute GVHD (2571)
Treatment of steroid non-responsive acute GVHD with alpha 1 anti-trypsin (AAT). A phase I/II study.

Investigator: Joachim Deeg, MD;   Conditions: Graft Versus Host Disease;    Status: Closed;   Study ID: NCT01523821

Brentuximab Vedotin for Steroid-Resistant Acute GVHD (FH 2589)
Phase II Study to Evaluate the Efficacy of Brentuximab Vedotin in Patients with Steroid-Resistant Acute GVHD

Investigator: Merav Bar, MD;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01616680

US-ATG-F to Prevent Chronic Graft Versus Host Disease (2523)
Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors

Investigator: Paul Martin, MD;   Conditions: GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01295710

Abatacept + Calcineurin Inhibitor + Methotrexate for Graft Versus Host Disease (2692)
Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial

Investigator: Leslie S Kean, MD/PhD ;   Conditions: Graft vs Host Disease;    Status: Recruiting;   Study ID: NCT01743131